Physician profile
Stephen H Landy
NPI 1528029618
$1,867,196.03
in general payments reported to CMS, 2019-2025
15 companies · $95K in 2025
The $95K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345K · 2020: $339K · 2021: $440K · 2022: $333K · 2023: $158K · 2024: $157K · 2025: $95K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $167K · Honoraria: $127K · Consulting Fee: $82K · Travel and Lodging: $29K · Food and Beverage: $5,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $166,962.50 |
| Honoraria | $126,790.00 |
| Consulting Fee | $82,177.05 |
| Travel and Lodging | $28,780.53 |
| Food and Beverage | $5,809.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385,161.07 | 2021-2025 | |
| Allergan, INC. | $348,525.00 | 2019-2022 | |
| Lilly USA, LLC | $275,880.49 | 2019-2024 | Emgality, Reyvow |
| Amgen INC. | $244,958.15 | 2019-2022 | |
| Lundbeck LLC | $222,827.89 | 2020-2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $109,256.02 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $94,414.42 | 2019-2022 | |
| Impel Pharmaceuticals INC. | $91,857.71 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $70,439.91 | 2022 | |
| Biodelivery Sciences International, INC. | $10,661.36 | 2021-2022 | |
| Promius Pharma LLC | $6,654.79 | 2019 | |
| Pfizer INC. | $5,996.00 | 2023-2025 | |
| Sentynl Therapeutics, INC. | $450.00 | 2019 | |
| Upsher-Smith Laboratories LLC | $78.19 | 2019 | |
| Supernus Pharmaceuticals, INC. | $35.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Landy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.